Print Page  |  Close Window

2017 Press Releases

Keyword Search
 

June 08, 2017

Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors read more

May 30, 2017

Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease read more

May 25, 2017

Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300 read more

May 24, 2017

Protagonist Therapeutics Receives $1.34 Million SBIR Funding for Development of Biomarkers of IL-23 Receptor Antagonist Activity read more

May 10, 2017

Protagonist Therapeutics Reports First Quarter 2017 Financial Results read more

May 04, 2017

Key Patent Issues Covering Protagonist Therapeutics' Oral Peptide IL-23 Receptor Antagonists, including the Development Candidate PTG-200 read more

April 20, 2017

Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week read more

March 09, 2017

Protagonist Therapeutics to Present at the Oppenheimer & Co. Healthcare Conference read more

March 07, 2017

Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results read more

March 02, 2017

Protagonist Therapeutics to Present at the Barclays Global Healthcare Conference read more

February 17, 2017

Protagonist Therapeutics Presents Data on Oral Peptide Drug Candidates at European Crohn's and Colitis Organization (ECCO) Congress read more

February 01, 2017

Protagonist Therapeutics to Participate in the Leerink Partners 6th Annual Global Healthcare Conference read more

January 17, 2017

Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis read more

January 05, 2017

Key Patent is Issued Covering Protagonist Therapeutics' Alpha4Beta7 Integrin Peptide Inhibitors including Oral Drug Candidate PTG-100 read more